menu

What Is the Totality of Evidence for IV Iron Treatment Outcomes in Patients with Heart Failure?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

What Is the Totality of Evidence for IV Iron Treatment Outcomes in Patients with Heart Failure?

2 chapters
Play All
0.50 credits
30 minutes
Chapter 1
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.50 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    Experts agree intravenous iron treatment for iron-deficient patients with heart failure can improve outcomes, but what are we learning from the recent clinical trials? Drs. Giuseppe Rosano, Marco Metra, Ovidiu Chioncel, and Antoni Bayés-Genís highlight the latest data as they discuss the recent updates to the ESC guidelines and provide expert analysis regarding clinical trials using IV iron. Discover the clinical relevance of the evidence from these trials in patients with heart failure and iron deficiency.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
    Professor of Cardiology and Consultant Cardiologist
    St. George’s Hospital NHS Trust University of London
    London, United Kingdom

    No relevant relationships reported.

    Faculty:
    Antoni Bayés-Genís, MD, PhD, FESC, FHFA
    Director de l'Institut del Cor
    Hospital Universitari Germans Trias i Pujol
    Catedràtic, Departament de Medicina, Universitat Autònoma de Barcelona
    Barcelona, Spain

    Consulting Fees: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Novartis, Roche Diagnostics

    Ovidiu Chioncel, MD, PhD
    Professor of Cardiology and Head of ICCU
    University of Medicine Carol Davila
    Bucharest, Romania

    Nothing to disclose at this time.

    Marco Metra, MD
    Professor of Cardiology and Director of the Institute of Cardiology
    Department of Medical and Surgical Specialties, Radiological Sciences and Public Health
    University and Civil Hospitals
    Brescia, Italy

    Nothing to disclose at this time.

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Review the latest guideline updates on IV iron presented at ESC 2023 (updated IV iron guidelines, Heart-FID)
    • Assess the clinical relevance of the HEART-FID trial despite missing the prespecified P value set by regulators
    • Evaluate the totality of evidence of IV iron trials with ferric carboxymaltose, including the clinical evidence vs newly released data in treating heart failure patients
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, nephrologists, and all other HCPs involved in the identification and treatment of patients with heart failure.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Experts agree intravenous iron treatment for iron-deficient patients with heart failure can improve outcomes, but what are we learning from the recent clinical trials? Drs. Giuseppe Rosano, Marco Metra, Ovidiu Chioncel, and Antoni Bayés-Genís highlight the latest data as they discuss the recent updates to the ESC guidelines and provide expert analysis regarding clinical trials using IV iron. Discover the clinical relevance of the evidence from these trials in patients with heart failure and iron deficiency.  

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Giuseppe M.C. Rosano, MD, PhD, FESC, FHFA
    Professor of Cardiology and Consultant Cardiologist
    St. George’s Hospital NHS Trust University of London
    London, United Kingdom

    No relevant relationships reported.

    Faculty:
    Antoni Bayés-Genís, MD, PhD, FESC, FHFA
    Director de l'Institut del Cor
    Hospital Universitari Germans Trias i Pujol
    Catedràtic, Departament de Medicina, Universitat Autònoma de Barcelona
    Barcelona, Spain

    Consulting Fees: Abbott, AstraZeneca, Bayer, Boehringer Ingelheim, CSL Vifor, Novartis, Roche Diagnostics

    Ovidiu Chioncel, MD, PhD
    Professor of Cardiology and Head of ICCU
    University of Medicine Carol Davila
    Bucharest, Romania

    Nothing to disclose at this time.

    Marco Metra, MD
    Professor of Cardiology and Director of the Institute of Cardiology
    Department of Medical and Surgical Specialties, Radiological Sciences and Public Health
    University and Civil Hospitals
    Brescia, Italy

    Nothing to disclose at this time.

    Reviewers/Content Planners/Authors:

    • Megan Clem has nothing to disclose.
    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Brian P. McDonough, MD, FAAFP, has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Review the latest guideline updates on IV iron presented at ESC 2023 (updated IV iron guidelines, Heart-FID)
    • Assess the clinical relevance of the HEART-FID trial despite missing the prespecified P value set by regulators
    • Evaluate the totality of evidence of IV iron trials with ferric carboxymaltose, including the clinical evidence vs newly released data in treating heart failure patients
  • Target Audience

    This activity is designed to meet the educational needs of cardiologists, primary care physicians, nephrologists, and all other HCPs involved in the identification and treatment of patients with heart failure.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of continuing medical education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.5 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule18 Apr 2024